PeptideStack
5.2kquestions
20kanswers
220users

Is 96.8% a realistic purity ceiling for tirzepatide given its chain length?

Asked 6 Jul 2026Modified 1 min agoViewed 5.3k times
11

Concretely: 96.8% · tirzepatide.

I want the working, not the result — I need to be able to redo it with different numbers.

I care about the precision as well as the value — I want to know how many figures are real.

Is my approach right even if my number is wrong?

purity
purity

Purity as chromatographic area per cent - the fraction of detected material that is your target peak. It says nothing about how much material is…

833 questions
hplc
hplc

Reverse-phase high-performance liquid chromatography, the workhorse purity method. Column chemistry, mobile-phase choice, gradient slope,…

503 questions
peptide-mapping
peptide-mapping

Enzymatic digestion followed by LC-MS/MS to confirm sequence rather than just mass. The method that catches a scrambled sequence or a D-amino-acid…

103 questions
tirzepatide
tirzepatide

A dual GIP and GLP-1 receptor agonist. Questions here cover the SURPASS and SURMOUNT programmes, the practical differences from a pure GLP-1…

370 questions
shareeditfollowflag
FB
askedfresh_bac9.7k166 Jul 2026

5 Answers

Sorted by votes
43

96.8 per cent is at the top of what stepwise synthesis delivers on a chain this long, and it is reachable rather than fictional. Every coupling is high-yielding and none is quantitative, so the deletion and truncation sequences that survive purification are what occupies the remaining 3.2 per cent. Above roughly 98 per cent you are fighting the purification rather than the synthesis, which is why a 96.8 per cent figure on tirzepatide deserves a method question — column, gradient, wavelength — rather than either belief or dismissal.

Identity and purity are orthogonal, and a high purity says almost nothing about whether the peak is actually what you think it is.

Sample solvent strength affects peak shape — if you inject in strong solvent on a gradient starting in weak solvent, the solvent peak can distort your main peak or create a false shoulder.

It helps to be literal here: the fraction of your main peak that is actually your target versus isomers, fragments or related sequences is invisible without complementary identity testing.

The Arrhenius relationship for peptide degradation is the basis of accelerated stability testing and also governs how quickly methods drift with temperature.

Compare purity within a single laboratory on the same method, never across laboratories.

edited 5 Aug 2026 by ilaria_bertone — added the method parameters

shareimprove this answerflag
IB
answeredilaria_bertone33k3830 Jul 2026
Sponsored

Sigma-Aldrich - Certified Reference Materials

Analytical standards and reagents with traceable certificates. Every quantitative result you read inherits the accuracy of the standard behind it.

Shop standards
29

The short answer is that two competent laboratories on identical material will disagree, and the disagreement is almost always explainable by method differences.

Temperature affects the dynamics of molecular conformation, and if a peptide has proline residues that interconvert on the chromatographic timescale, the peak will split or shoulder at low temperature and collapse at high temperature.

More usefully, mass on column affects detector linearity and peak overlap — overloading broadens peaks and hides neighbours, while underloading improves resolution but loses sensitivity.

Inter-laboratory studies on identical peptide material routinely find half-a-per-cent to a full-per-cent spreads in reported purity on the same sample.

If you are ranking vendors, specify a method and have all samples tested at the same place.

shareimprove this answerflag
TG
answeredtandem_gradient61k24817 Jul 2026
21

To be exact about it, reporting threshold is convention and not chemistry, which is why two certificates with different thresholds disagree by a tenth of a point or more.

Detection wavelength matters because 214 nm sees the peptide backbone while 280 nm sees only aromatic side chains — so truncation impurities lacking a tryptophan are invisible at 280 nm.

It helps to be literal here: retention time is sequence-specific and method-specific, so comparing your result to a supplier value using a different method is meaningless without method documentation.

The practical summary: ask for the chromatogram and the method, and ignore the headline number until you have both.

shareimprove this answerflag
GA
answeredgrainne_ahearn50k388 Jul 2026
3Small correction: the limit of quantitation, not the limit of detection, is the relevant one there. – Dr_Bram_Verhoeven 8 months ago
2Thank you — this is the answer I was looking for. – Dr_Elias_Weiss 6 months ago
add a comment
17

The honest answer is that the achievable range of plausible purity figures for a given vial is wider than most people expect.

Mobile phase additive choice affects ionisation and peak shape — TFA gives sharp peaks but suppresses mass spectrometry signal, formic acid gives worse peaks but preserves signal.

The ICH Q3A impurity thresholds and the relevant pharmacopoeial chapters all specify method validation requirements that almost no research-grade certificate claims to meet.

If you only pay for one test, pay for quantified content. Purity is the number everyone quotes and content is the number that changes what you do.

shareimprove this answerflag
DW
answeredDr_Elias_Weiss25k2719 Jul 2026
1

Gradient slope is the most powerful parameter and almost nobody mentions it, which is why two reports on the same material disagree by a point.

Gradient slope controls resolution, and gentler slopes resolve co-eluting impurities into separate peaks — so the better method reports the worse purity number.

In practice: ask for the chromatogram, check the method section, check the lot number against the vial, and set your accept threshold before you see the result rather than after.

shareimprove this answerflag
DV
answeredDr_Bram_Verhoeven84k24810 Jul 2026
4Same experience here, different supplier. – h_pergande 16 days ago
3The distinction between purity and content cannot be repeated often enough here. – lipid_panel_q 9 months ago
add a comment

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.